Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in GCC has been steadily growing in recent years, driven by various factors such as an aging population and an increase in the prevalence of cardiovascular diseases.
Customer preferences: Patients in the GCC region are increasingly opting for anticoagulant therapy as a preventative measure against stroke and other cardiovascular diseases. The preference for non-vitamin K antagonist oral anticoagulants (NOACs) has also been on the rise due to their ease of use and lower risk of bleeding compared to traditional anticoagulants.
Trends in the market: Saudi Arabia has been the largest market for anticoagulants in the GCC, with a significant portion of the population being over the age of 65. This trend is expected to continue, with the aging population driving demand for anticoagulant therapy. Furthermore, the COVID-19 pandemic has increased the risk of thrombosis, leading to a surge in demand for anticoagulants.
Local special circumstances: The GCC region has a high prevalence of obesity, diabetes, and hypertension, which are risk factors for cardiovascular diseases. This has contributed to the growing demand for anticoagulant therapy. Additionally, the region has a high incidence of consanguineous marriages, which can lead to an increased risk of genetic disorders such as thrombophilia, further driving demand for anticoagulant therapy.
Underlying macroeconomic factors: The GCC countries have been investing heavily in their healthcare infrastructure, with a focus on improving access to healthcare services. This has led to increased awareness about the importance of preventive healthcare and early detection of diseases, including cardiovascular diseases. Additionally, the region has a high disposable income, which has enabled patients to afford the high cost of anticoagulant therapy. The GCC countries have also been diversifying their economies, which has led to an increase in foreign investment and a growing healthcare sector. This has created opportunities for pharmaceutical companies to expand their presence in the region and tap into the growing demand for anticoagulant therapy.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
